Evidence map›Paper›PMID 16779672›Full record

ArticleCellular and molecular neurobiology

Transdifferentiated mesenchymal stem cells as alternative therapy in supporting nerve regeneration and myelination.

Gerburg Keilhoff, Felix Stang, Alexander Goihl, Gerald Wolf, Hisham Fansa

Registry-linked trialOpen access · greenAbstract readEvaluation Study
In one paragraph

Article in Cellular and molecular neurobiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02387749 (Effect Of Mesenchymal Stem Cells Transfusion on the Peripheral Neuropathy in Diabetic Patients Measured by Nerve Conduction.), which is not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02387749 nacompletednot on this map

Effect Of Mesenchymal Stem Cells Transfusion on the Peripheral Neuropathy in Diabetic Patients Measured by Nerve Conduction.

TypeinterventionalSponsorCairo UniversityRan2014 to 2016Enrolled10ConditionsDiabetic Peripheral NeuropathyArmsmesenchymal stem cells
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 154 citations in OpenAlex.

  1. Review
  2. Stem cell and gene therapies for leukodystrophies.Molecular therapy. Methods & clinical development · 2025
    Review
  3. Article
  4. Overview of emerging therapies for demyelinating diseases.World journal of clinical cases · 2024
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. AnPathology oncology research : POR · 2021
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Stem cell therapy for nerve injury.World journal of stem cells · 2017
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Gerburg KeilhoffInstitute of Medical Neurobiology, Otto-von-Guericke University, Magdeburg, Germany. gerburg.keilhoff@medizin.uni-magedeburg.de
Felix Stang
Alexander Goihl
Gerald Wolf
Hisham Fansa
Otto-von-Guericke University Magdeburg · DEKlinikum Bielefeld · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDemyelination plays a crucial role in neurodegenerative processes and traumatic disorders. One possibility to achieve remyelination and subsequent restoration of neuronal function is to provide an exogenous source of myelinating cells via transplantation. In this context, mesenchymal stem cells (MSCs) have attracted interest. They are multipotent stem cells that differentiate into cells of the mesodermal lineage like bone, cartilage, fat, and muscle. Although adult, their differentiation potential is remarkable, and they are able to transdifferentiate.

methodsWe transformed cultivated rat MSCs into myelinating cells by using a cytokine cocktail. Transdifferentiated MSCs were characterized by an enhanced expression of LNGF-receptor, Krox20, and CD104, and a decreased expression of BMP receptor-1A as compared to untreated MSCs. The myelinating capacity was evaluated in vitro and in vivo. Therefore, PC12 cells, normally unmyelinated, were cocultivated with MSCs, transdifferentiated MSCs, and Schwann cells, or the respective cells were grafted into an autologous muscle conduit bridging a 2-cm gap in the rat sciatic nerve. Myelination of PC12 cells was demonstrated by electron microscopy. In vivo, after 3 and 6 weeks regeneration including myelination was monitored histologically and morphometrically. Autologous nerves and cell-free muscle grafts were used as control.

resultsSchwann cells and transdifferentiated MSCs were able to myelinate PC12 cells after 14 days in vitro. In vivo, autologous nerve grafts demonstrated the best results in all regenerative parameters. An appropriate myelination was noted in the Schwann cell groups and, albeit with restrictions, in the transdifferentiated MSC groups, while regeneration in the MSC groups and in the cell-free groups was impaired.

conclusionOur findings demonstrate that it may be possible to differentiate MSCs into therapeutically useful cells for clinical applications in myelin defects.

Indexed as

Cell DifferentiationMesenchymal Stem Cell TransplantationNerve RegenerationAnimalsCells, CulturedMesenchymal Stem CellsMyelin SheathNeurodegenerative DiseasesPC12 CellsRatsRats, WistarSchwann CellsSciatic NerveSpinal Cord InjuriesTransplantation, Homologous

Identifiers

PMID16779672
PMCPMC11881818
OpenAlexW2081321708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.